Pharmaceuticals

FDA Grants Fast Track Designation to Abdella Therapeutics’ Advanced Small Cell Lung Cancer Treatment

bexib
By bexib 0 Min Read

The new therapy, ABD-147, uses advanced antibody engineering to deliver actinium-225 to solid tumors expressing DLL3, a protein found in neuroendocrine tumors.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article NoOnes Bitcoin Philosophy: Everybody Eats
Next Article Bitcoin Magazine and Look into Bitcoin Team Up to Release Enhanced Bitcoin Magazine Pro – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Why this Chinese unicorn is betting big on B2B cross-border payments in Southeast Asia
Fintech
Seamless integration with legacy systems and improved customer satisfaction for wholesalers, MGAs, and brokers
Insurance
HSBC helps Singapore’s SMEs become more sustainable with new financing
Fintech
4 things you need to know about E&O Insurance for insurance agents
Insurance